TY - JOUR
T1 - Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools
AU - Salomone, S.
AU - Potts, E. M.
AU - Tyndall, S.
AU - Ip, P. C.
AU - Chun, J.
AU - Brinkmann, V.
AU - Waeber, C.
PY - 2008/1
Y1 - 2008/1
N2 - Background and purpose: Sphingosine 1-phosphate (S1P) selectively and potently constricts isolated cerebral arteries, but this response has not been pharmacologically characterized. Experimental approach: The receptor subtype(s) involved in S1P-induced cerebrovascular constriction were characterized using genetic (S1P 2 and S1P 3 receptor null mice) and pharmacological tools (phospho-FTY720, a S1P 1/3/4/5 receptor agonist; SEW2871, a S1P 1 receptor agonist, JTE-013, a S1P 2 receptor antagonist, VPC23019, a S1P 1/3 receptor antagonist). Isolated basilar or peripheral (femoral, mesenteric resistance) arteries, from either rat or mouse, were studied in a wire myograph. Key results: S1P concentration-dependently constricted basilar artery in rat, wild-type (WT) and S1P 2 null mice, but barely affected vascular tone in S1P 3 null mice. Vasoconstriction to U46619 (a thromboxane analogue) or to endothelin-1 did not differ between WT, S1P 2 and S1P 3 null mice. JTE-013 inhibited not only S1P-induced vasoconstriction, but also KCl-, U46619- and endothelin-1-induced constriction. This effect was observed in WT as well as in S1P 2 null mice. VPC23019 increased the concentration-dependent vasoconstriction to S1P in both rat and mouse basilar arteries with intact endothelium, but not in rat basilar artery without endothelium. Phospho-FTY720 concentration-dependently constricted rat basilar arteries, but not femoral or mesenteric resistance arteries, while SEW2871 did not induce any response in the same arteries. Conclusions and implications: S1P constricts cerebral arteries through S1P 3 receptors. The purported S1P 2 receptor antagonist JTE-013 does not appear to be selective, at least in rodents. Enhancement of S1P-induced contraction by VPC23019 might be related to blockade of S1P 1 receptors and NO generation.
AB - Background and purpose: Sphingosine 1-phosphate (S1P) selectively and potently constricts isolated cerebral arteries, but this response has not been pharmacologically characterized. Experimental approach: The receptor subtype(s) involved in S1P-induced cerebrovascular constriction were characterized using genetic (S1P 2 and S1P 3 receptor null mice) and pharmacological tools (phospho-FTY720, a S1P 1/3/4/5 receptor agonist; SEW2871, a S1P 1 receptor agonist, JTE-013, a S1P 2 receptor antagonist, VPC23019, a S1P 1/3 receptor antagonist). Isolated basilar or peripheral (femoral, mesenteric resistance) arteries, from either rat or mouse, were studied in a wire myograph. Key results: S1P concentration-dependently constricted basilar artery in rat, wild-type (WT) and S1P 2 null mice, but barely affected vascular tone in S1P 3 null mice. Vasoconstriction to U46619 (a thromboxane analogue) or to endothelin-1 did not differ between WT, S1P 2 and S1P 3 null mice. JTE-013 inhibited not only S1P-induced vasoconstriction, but also KCl-, U46619- and endothelin-1-induced constriction. This effect was observed in WT as well as in S1P 2 null mice. VPC23019 increased the concentration-dependent vasoconstriction to S1P in both rat and mouse basilar arteries with intact endothelium, but not in rat basilar artery without endothelium. Phospho-FTY720 concentration-dependently constricted rat basilar arteries, but not femoral or mesenteric resistance arteries, while SEW2871 did not induce any response in the same arteries. Conclusions and implications: S1P constricts cerebral arteries through S1P 3 receptors. The purported S1P 2 receptor antagonist JTE-013 does not appear to be selective, at least in rodents. Enhancement of S1P-induced contraction by VPC23019 might be related to blockade of S1P 1 receptors and NO generation.
KW - Basilar artery
KW - FTY720
KW - JTE-013
KW - S1P
KW - SEW2871
KW - VPC23019
UR - https://www.scopus.com/pages/publications/37849001331
U2 - 10.1038/sj.bjp.0707581
DO - 10.1038/sj.bjp.0707581
M3 - Article
C2 - 18026125
AN - SCOPUS:37849001331
SN - 0007-1188
VL - 153
SP - 140
EP - 147
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 1
ER -